REGULATORY STATEMENT:
The Sonablate® 500 has been approved for the treatment of prostate cancer in Canada since 2005.
Sonablate® has 510(K) clearance in the U.S. under a De Novo regulatory classification and is indicated for the transrectal high intensity focused ultrasound (HIFU) ablation of prostatic tissue.